Expanded Access to Upadacitinib

Status No longer available

Clinical Trial Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04159597
Study type	Expanded Access
Source	AbbVie
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03151148` - Targeted Microbiome Transplant in Atopic Dermatitis	Phase 1/Phase 2
Active, not recruiting	`NCT05456529` - Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis	Phase 3
Completed	`NCT04056130` - A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects	Phase 1
Recruiting	`NCT04173442` - Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
Completed	`NCT05372653` - A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis	Phase 3
Completed	`NCT03168113` - Atopic Dermatitis (AD) and Food Allergy	N/A
Terminated	`NCT03389893` - Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis	Phase 4
Recruiting	`NCT04541810` - A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Completed	`NCT02357940` - Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema	N/A
Recruiting	`NCT05667623` - To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD	Phase 3
Recruiting	`NCT05650320` - To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD	Phase 3
Completed	`NCT01979016` - Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)	Phase 2
Withdrawn	`NCT04666675` - A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil	Phase 3
Active, not recruiting	`NCT05959083` - Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis